PRADAXA LAWSUIT UPDATE JULY 2012

 PRADAXA (DABIGATRAN ETEXILATE) LAWSUIT UPDATE

Legal cases against BOEHRINGER INGELHEIM, the manufacturer of PRADAXA (DABIGATRAN ETEXILATE) have begun to gain momentum in the United States. As a result, a petition to organize the litigation in a Multi-District Litigation (MDL) in the Federal court system was filed. Naturally, this lead to interested parties presenting arguments, before the Judicial Panel on Multi-District Litigation (JPML), requesting particular venues. Regardless of where the JPML directs the formation of an MDL, it is clear that PRADAXA BLEEDS and related cases will become the subject of litigation nationwide.

Following the publicization of international concerns in November 2011, as well as repeated reports from the ISMP (highlighted below), it is possible that sales of the anti-coagulant may be slowing as word spreads to providers, prescribers and patients of the dangers associated with the use of the novel anti-coagulant.

PRADAXA SALES CLIFF - LAWSUIT UPDATE JULY 2012.

PRADAXA SALES CLIFF - LAWSUIT UPDATE JULY 2012.

The graphic above, from DRUGS.com, appears to show a drop off in “units”. Whether this downward trend will continue through 2012 remains to be seen. If it is related to growing suspicions and concerns over the future of PRADAXA (DABIGATRAN ETEXILATE) is unclear. Based upon IMSP’s past evaluation of FDA data tying the anti-coagulant to adverse events this trend is not surprising.

FREE PRADAXA CASE EVALUATIONS  ARE AVAILABLE THROUGH THE USE OF THE CONTACT FORM BELOW FROM THE SPONSOR OF THIS SITE.

IS PRADAXA "PROGRESS" AS ADVERTISED OR NOT?